Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.61 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13885040 | 0.88 | GSK3B (0.66) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL13998528 | 0.84 | GSK3B (0.62) | GSK3BCDK2CCNE1 | |
| SCHEMBL11931056 | 0.76 | GSK3B (0.76) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL13309048 | 0.75 | GSK3B (0.66) | GSK3BCDK2 | |
| SCHEMBL13309213 | 0.75 | GSK3B (0.58) | GSK3BCDK2 | |
| SCHEMBL13309390 | 0.75 | GSK3B (0.62) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL11936842 | 0.74 | GSK3B (0.51) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL13146372 | 0.74 | GSK3B (0.55) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL12954309 | 0.74 | GSK3B (0.56) | GSK3BCDK2CCNE1CCNA2CCNA1 | |
| SCHEMBL13993125 | 0.74 | CDK2 (0.67) | GSK3BCDK2CCNA2CCNA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934224-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7514442-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514442-B2 | Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1534712-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007044420-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205308-B2 | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-04-17 | — | — | US | disclosed |